Losartan- Hanmi Pharmaceuticals

Drug Profile

Losartan- Hanmi Pharmaceuticals

Alternative Names: HGP 0608

Latest Information Update: 05 Oct 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Hanmi Pharmaceutical
  • Class Antihypertensives; Biphenyl compounds; Heart failure therapies; Imidazoles; Ischaemic heart disorder therapies; Small molecules; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Dyslipidaemias; Hypertension

Most Recent Events

  • 01 Jun 2016 Hanmi Pharmaceutical completes a phase III trial in Dyslipidaemias in South Korea (NCT02899455)
  • 01 Jun 2016 Hanmi Pharmaceutical completes a phase III trial in Hypertension (Combination therapy) in South Korea(NCT02899455)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top